Breaking News

Aldena, PCI Pharma Partner on Dermatological Diseases

PCI will formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions.

Aldena Therapeutics, a private biotech company pioneering siRNA-based therapies for dermatological indications, has selected PCI Pharma Services, a global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions. ALD-102 is currently in preclinical trials and represents the most advanced therapy in Aldena’s pipeline. PCI specializes in developme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters